Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $17.00.
A number of research analysts recently weighed in on the company. Guggenheim lifted their target price on Cabaletta Bio from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Cabaletta Bio in a research note on Monday, April 20th. Morgan Stanley reduced their price objective on Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 24th. Wall Street Zen cut Cabaletta Bio from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 target price on shares of Cabaletta Bio in a research report on Monday.
Get Our Latest Research Report on Cabaletta Bio
Institutional Trading of Cabaletta Bio
A number of institutional investors have recently added to or reduced their stakes in CABA. Kestra Advisory Services LLC acquired a new stake in shares of Cabaletta Bio in the first quarter valued at about $32,000. China Universal Asset Management Co. Ltd. purchased a new position in Cabaletta Bio in the 4th quarter worth approximately $34,000. ANTIPODES PARTNERS Ltd acquired a new stake in Cabaletta Bio in the fourth quarter valued at approximately $38,000. Private Advisor Group LLC grew its position in Cabaletta Bio by 22.4% in the first quarter. Private Advisor Group LLC now owns 18,025 shares of the company's stock valued at $48,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of Cabaletta Bio during the fourth quarter valued at approximately $43,000.
Cabaletta Bio Stock Up 7.2%
Shares of Cabaletta Bio stock opened at $4.00 on Friday. Cabaletta Bio has a fifty-two week low of $1.11 and a fifty-two week high of $4.23. The firm has a market cap of $445.28 million, a PE ratio of -1.75 and a beta of 3.18. The business's fifty day moving average is $3.14 and its two-hundred day moving average is $2.72.
Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. Equities research analysts anticipate that Cabaletta Bio will post -1.5 EPS for the current year.
Cabaletta Bio Company Profile
(
Get Free Report)
Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.
The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
